Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imbokodo: Ad26.Mos4.HIV and Clade C gp140 Vaccine in Women
NCT03060629Phase 2Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2017
- Primary completion
- Feb 2022
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 5
01
Overview
A Phase 2 trial of Ad26.Mos4.HIV, clade C gp140 in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Janssen Pharmaceutical. Started Nov 2017; status: terminated.
02
Drugs
Ad26.Mos4.HIVclade C gp140
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT03060629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03060629.